Trial Profile
A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma of the Colon
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colon cancer
- Focus Registrational; Therapeutic Use
- 22 Jan 2022 Results of association of VEGFR, VEGFA, and CD31, with clinical outcomes and treatment benefit in dMMR and pMMR, presented at the 2022 Gastrointestinal Cancers Symposium
- 08 Jun 2021 Results (n=1509 )evaluating to quantify the different molecules of TIME including T cells, macrophages, and immune checkpoint proteins (ICPs), and determine their association with clinical outcomes and treatment benefit, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 16 Jan 2020 Results (n=6501) of pooled analysis of six clinical trials (NCT00079274; NCT00096278; NCT00004931; NCT00275210; NCT00265811; NCT00112918) examining the change of outcomes over 10-year period in patients with stage 3 colon cancer who were treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database, published in the Annals of Oncology.